Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test Multiple Myeloma MRD Panel By Flowcytometry is 14 days.

What are the prerequisites for the test Multiple Myeloma MRD Panel By Flowcytometry

  • Patient must have a confirmed diagnosis of Multiple Myeloma
  • Test must be ordered by a healthcare provider
  • Sample type required: Bone marrow aspirate or peripheral blood
  • Minimum volume of sample required: 2-5 mL
  • Sample must be collected in a lavender top (EDTA) tube
  • Sample must be transported to the laboratory within 24 hours of collection

What are the measure values for the test Multiple Myeloma MRD Panel By Flowcytometry

  • Positive: ≥0.01% of cells
  • Negative: <0.01% of cells

What does this test Multiple Myeloma MRD Panel By Flowcytometry identify?

  • Test Name: Multiple Myeloma MRD Panel By Flowcytometry
  • Identifies: This test is used to detect and quantify Minimal Residual Disease (MRD) in patients with Multiple Myeloma.
  • Details: MRD refers to the small number of cancer cells that may remain in the body during or after treatment for Multiple Myeloma. Detecting MRD can help predict disease relapse or progression earlier than traditional methods. Flow cytometry is a technique that uses fluorescently-labeled antibodies to identify and quantify specific cell populations, including cancer cells in Multiple Myeloma.

Why is this test Multiple Myeloma MRD Panel By Flowcytometry taken?

Multiple Myeloma MRD Panel By Flowcytometry

Reason for Test:

The Multiple Myeloma MRD Panel By Flowcytometry test is taken to assess the minimal residual disease (MRD) in patients with multiple myeloma. MRD refers to the small number of cancer cells that may remain in the body after treatment, even when the patient is in remission. Detecting MRD can help doctors determine the effectiveness of treatment and monitor disease progression.

This test is particularly important in multiple myeloma, as the disease can have periods of remission followed by relapse. Monitoring MRD levels can help guide treatment decisions and predict the likelihood of relapse.

Flow cytometry is a technique used to analyze and count cells in a sample, making it a valuable tool for assessing MRD in multiple myeloma patients. By using specific markers to identify cancer cells, flow cytometry can provide detailed information about the presence of MRD in the patient's bone marrow or blood.

No FAQs available.

Customer Google Rating